Ocimed signs distribution agreement for Ocimum's Spoligotyping kit
Bangalore: Ocimed signed a distribution agreement for Ocimum Biosolutions' research product, the Spoligotyping kit. Preferred by customers in tuberculosis research, pharma companies, and in many other sectors, the Spoligotyping Kit (spacer oligonucleotide typing kits) can detect and type Mycobacterium tuberculosis complex bacteria in clinical samples.
Ocimed, which is based in Friedberg, Germany, will distribute the kits in Europe. The internationally acclaimed research aid has customers in India as well as across the globe, especially in the United States and in Asia. While the kits have many buyers in Europe, this strategic move aims at increasing the customer base in that region while ensuring better quality of service to the existing customers.
Ms Anu Acharya, CEO, Ocimum Biosolutions, said, "Our Spoligotyping Kit has been sold in more than 30 countries for over 10 years and has over 150 publications referencing it. With the growing threat of TB worldwide, we found that Ocimed with its focus in this area a very suitable partner."
